Michael Weiner

Education

B.Sci., Pennsylvania State University (Microbiology and Immunology), Ph.D., Cornell University (Genetics, minors in Biochemistry and Microbiology), Postdoc., Cornell University (Physical Chemistry, protein structure and refolding research)

Notable Inventions

  • M.BamHI (Ph.D. thesis and Post-doc, Cornell Univ.. licensed to NEB)
  • QuikChange Mutagenesis (Stratagene, acquired by Agilent)
  • Emulsion PCR and Droplet PCR 454 (acquired by Roche) and RainDance Technologies & GnuBio (both acquired by BioRad), enabling technology for single-cell analysis)
  • NextGen DNA Sequencing (454 instrument – acquired by Roche)
  • NextGen Protein Sequencing (Encodia, a NextGen Protein sequencing instrument)
  • Site-directed antibodies (Abbratech, the subject of this presentation)

Notable Inventions

Member, Nuclear Receptors team (GlaxoSmithKline), Tuberous Sclerosis Complex (TSC) Research. [developed angiomyolipoma cell line (The Rothberg Institute)]